

110TH CONGRESS  
1ST SESSION

# H. R. 1743

To establish the National Center on Liver Disease Research, and for other purposes.

---

## IN THE HOUSE OF REPRESENTATIVES

MARCH 28, 2007

Mr. LYNCH (for himself, Mr. KING of New York, Mr. McCOTTER, Mr. GRIJALVA, Mr. OLVER, and Mr. McNULTY) introduced the following bill; which was referred to the Committee on Energy and Commerce

---

## A BILL

To establish the National Center on Liver Disease Research, and for other purposes.

1       *Be it enacted by the Senate and House of Representa-*  
2       *tives of the United States of America in Congress assembled,*

3       **SECTION 1. SHORT TITLE.**

4       This Act may be cited as the “Liver Research En-  
5       hancement Act of 2007”.

6       **SEC. 2. FINDINGS.**

7       The Congress finds as follows:

8               (1) An estimated 30,000,000 people in the  
9       United States are affected by a liver or liver-related  
10      disease.

1           (2) In excess of \$15,000,000,000 is spent annu-  
2 ally to provide medical care for people in the United  
3 States with hepatitis C. This cost is projected to  
4 grow substantially over the next decade without a  
5 vaccine, cure, or the discovery of better treatments.

6           (3) There are over 4,000,000 people in the  
7 United States who are or have been infected with  
8 hepatitis C, 3,200,000 of whom are chronically in-  
9 fected.

10          (4) Due to limited research, current treatments  
11 for hepatitis C are effective in approximately 50 per-  
12 cent of the cases.

13          (5) A vaccine has not been developed for hepa-  
14 titis C.

15          (6) There are 10,000 to 12,000 deaths each  
16 year due to hepatitis C, and the annual death total  
17 is projected to triple absent increased public health  
18 and research interventions.

19          (7) Hepatitis C is the leading cause of death  
20 among people co-infected with HIV.

21          (8) Chronic infection with hepatitis B or C is  
22 associated with an increased incidence of primary  
23 liver cancer, once a rare malignancy in the United  
24 States.

1           (9) There are 1,400,000 people in the United  
2 States who have been infected with hepatitis B.

3           (10) One out of 10 Asian and Pacific-Islander  
4 Americans are chronically infected with hepatitis B.

5           (11) It is estimated that as many as 20 percent  
6 of Americans have fatty liver disease which can lead  
7 to cirrhosis and liver failure.

8           (12) There are 15,000 children hospitalized in  
9 the United States each year due to liver disease.

10          (13) The only option for many individuals with  
11 advanced or chronic liver disease is a liver trans-  
12 plant.

13          (14) Approximately 17,000 people in the United  
14 States are on the waiting list for a liver transplant,  
15 but because of the limited supply of livers available  
16 for transplantation, only approximately 6,000 liver  
17 transplants are performed each year.

18          (15) There are 1,300 people in the United  
19 States who die each year waiting for a liver trans-  
20 plant.

21          (16) To address the public health threat posed  
22 by liver disease, there is a need for the establishment  
23 of a National Center on Liver Disease Research to  
24 provide dedicated scientific leadership, to create a

1 research action plan, and to ensure the funding of  
2 the scientific opportunities identified by the plan.

3 **SEC. 3. NATIONAL CENTER ON LIVER DISEASE RESEARCH.**

4 Subpart 3 of part C of title IV of the Public Health  
5 Service Act (42 U.S.C. 285c, et seq.) is amended by add-  
6 ing at the end the following:

7 “NATIONAL CENTER ON LIVER DISEASE RESEARCH

8 “SEC. 434B. (a) ESTABLISHMENT.—There is estab-  
9 lished the National Center on Liver Disease Research  
10 (hereafter in this section referred to as the ‘Center’) in  
11 the National Institute of Diabetes and Digestive and Kid-  
12 ney Diseases.

13 “(b) DIRECTOR.—The Center shall be headed by a  
14 Director, who shall be appointed by the Director of the  
15 Institute, in consultation with the Director of NIH, from  
16 among individuals with the highest scientific credentials.  
17 The Director of the Center shall report directly to the Di-  
18 rector of the Institute.

19 “(c) DUTIES.—To ensure the development of in-  
20 creased understanding of and better treatments and cures  
21 for liver diseases through a dedicated scientific leadership  
22 and an adequate allocation of resources, the Director  
23 shall—

24 “(1) assist the Liver Disease Research Advisory  
25 Board to develop the Liver Disease Research Action  
26 Plan; and

1           “(2) encourage and coordinate the implementa-  
2           tion of the Plan by the national research institutes,  
3           including by issuing research solicitations and by  
4           using all other available mechanisms.

5           “(d) LIVER DISEASE RESEARCH ADVISORY  
6 BOARD.—

7           “(1) ESTABLISHMENT.—Not later than 90 days  
8           after the date of the enactment of the Liver Re-  
9           search Enhancement Act of 2007, the Director of  
10          NIH shall establish a board to be known as the  
11          Liver Disease Research Advisory Board (hereafter in  
12          this section referred to as the ‘Advisory Board’).

13          “(2) DUTIES.—The Advisory Board shall advise  
14          and assist the Director of the Center concerning  
15          matters relating to liver disease research, including  
16          by developing and revising the Liver Disease Re-  
17          search Action Plan in accordance with subsection  
18          (e).

19          “(3) VOTING MEMBERS.—The Advisory Board  
20          shall be composed of 18 voting members appointed  
21          by the Director of NIH, in consultation with the Di-  
22          rector of the Institute, of whom 12 shall be eminent  
23          scientists and 6 shall be lay persons. The Director  
24          of NIH, in consultation with the Director of the In-

1       stitute, shall select 1 of the members to serve as the  
2       Chair of the Advisory Board.

3               “(4) EX OFFICIO MEMBERS.—The Director of  
4       NIH shall appoint each director of a national re-  
5       search institute that funds liver disease research to  
6       serve as a nonvoting, ex officio member of the Advi-  
7       sory Board. The Director of NIH shall invite 1 rep-  
8       resentative of the Centers for Disease Prevention  
9       and Control, 1 representative of the Food and Drug  
10      Administration, and 1 representative of the Depart-  
11      ment of Veterans Affairs to serve as such a member.  
12      Each ex officio member of the Advisory Board may  
13      appoint an individual to serve as that member’s rep-  
14      resentative on the Advisory Board.

15              “(e) LIVER DISEASE RESEARCH ACTION PLAN.—

16              “(1) DEVELOPMENT.—Not later than 15  
17      months after the date of the enactment of the Liver  
18      Research Enhancement Act of 2007, the Advisory  
19      Board shall develop (with appropriate support from  
20      the Director and staff of the Center) a comprehen-  
21      sive plan for the conduct and support of liver disease  
22      research to be known as the Liver Disease Research  
23      Action Plan. The Advisory Board shall submit the  
24      Plan to the Director of NIH and the head of each

1 institute or center within the National Institutes of  
2 Health that funds liver disease research.

3 “(2) CONTENT.—The Liver Disease Research  
4 Action Plan shall identify scientific opportunities  
5 and priorities of liver disease research necessary to  
6 increase understanding of and to prevent, cure, and  
7 develop better treatment protocols for liver diseases.

8 “(3) REVISION.—The Advisory Board shall re-  
9 vise every 3 years the Liver Disease Research Action  
10 Plan, but shall meet annually to review progress and  
11 to amend the Plan as may be appropriate because  
12 of new scientific discoveries.

13 “(f) ALLOCATION OF FUNDS.—Subject to the avail-  
14 ability of appropriations, the Director of each institute or  
15 center within the National Institutes of Health shall allo-  
16 cate to liver disease research through peer-reviewed meth-  
17 ods, the amounts necessary to fund existing scientific re-  
18 search opportunities and, subject to completion and subse-  
19 quent updates of the Liver Disease Research Action Plan,  
20 amounts adequate to carry out the recommendations of  
21 the Plan.”.

○